Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF

Catalog #: AVI10460 Datasheet / COA / SDS

Biotinylated

Catalog #	Availability	Size / Price	Qty
AVI10460-050

Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein Binding Activity

2 Images

All VEGFR2/KDR/Flk-1 Proteins and Enzymes

Product Details

Supplemental Products

Reviews

Summary Product Datasheets Carrier Free Data Images Reconstitution Calculator Background Related Research Areas

Recombinant Human VEGFR2/KDR/Flk-1 Fc Avi-tag Protein, CF Summary

Learn more about Avi-tag Biotinylated Proteins

Product Specifications

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

Activity

Measured by its binding ability in a functional ELISA. When Recombinant Human VEGF165 (Catalog # 293-VE) is immobilized at 1 µg/mL (100 µL/well), Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (Catalog # AVI10460) binds with an ED₅₀ of 4-40 ng/mL.

Source

Human embryonic kidney cell, HEK293-derived human VEGFR2/KDR/Flk-1 protein

Human VEGFR2/KDR/Flk-1 (Ala20-Glu764) Accession # AAC16450.1	IEGRMD	Human IgG₁ (Pro100-Lys330)	Avi-tag
N-terminus			C-terminus

Accession #

AAC16450.1

N-terminal Sequence
Analysis

Ala20

Structure / Form

Disulfide-linked homodimer, biotinylated via Avi-tag

Predicted Molecular Mass

111 kDa

SDS-PAGE

145-165 kDa, under reducing conditions

Product Datasheets

AVI10460

Product Datasheet

COA

SDS

Carrier Free

What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

AVI10460

Formulation	Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution	Reconstitute at 500 μg/mL in PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage:	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Scientific Data

Binding Activity

View Larger

When Recombinant Human VEGF 165 (293-VE) is immobilized at 1 μg/mL (100 μL/well), Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (AVI10460) binds with an ED50 of 4-40 ng/mL.

SDS-PAGE

View Larger

2 μg/lane of Biotinylated Recombinant Human VEGFR2/KDR/Flk-1 Fc Chimera Avi-tag (AVI10460) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 145-165 kDa and 290-330 kDa, respectively.

Reconstitution Calculator

Background: VEGFR2/KDR/Flk-1

Vascular endothelial Growth Factor Receptor 2 (VEGFR2), also known as FLK-1, KDR, and CD309, is a type I single-pass membrane receptor. Mature VEGFR2 contains a 745 amino acid extracelluar domain with seven immunoglobulin-like repeats, 21 transmembrane domain and 571 cytoplasmic domain. Within the extracellular domain, human VEGFR2 shares 80% homology with that of mouse and rat. VEGFR2, VEGFR1(Flt-1) and VEGFR3(Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors have almost exclusive expression in the endothelial cells and play essential roles in vasculogenesis and angiogenesis. VEGFR2 is the receptor for VEGF-A, VEGF-C, VEGF-D, and VEGF-E (viral homologs) (1, 2). Monomeric VEGFR2 dimerizes after binding to dimeric ligand and phosphorylate the Tyr in the cytoplasmic domain (3). VEGFR2 can also form heterodimer with VEGFR1 and VEGFR3 (4-6). Alternative splicing isoforms 2 and 3 which lack the transmembrane and cytoplasmic domains function as decoy receptors (7, 8). Targeting the signaling pathways of VEGFR1 and VEGFR2 are potential therapeutic targets for the treatment of inflammation and multiple tumors including breast, gastric, and lung carcinomas (9-12). Cancer immunotherapies using VEGF and VEGFR2 monoclonal antibodies may also be effective in combination with programmed cell death protein 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) immune checkpoint blockade (13). Our Avi-tag Biotinylated VEGFR2 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References

Ferra, N. and Davis-Smyth, T. (1997) Endocr. Rev. 18:4.
Wise, L.M. et al. (2012) Cell Microbiol. 13:1376.
Lepanen, V.M. et al. (2010) Proc. Natl. Acad. Sci. USA 107:2425.
Cai, M. et al. (2017) Vascul. Pharmacol. 88:11.
Nilsson, I. et al. (2010) EMBO J. 29:1377.
Dixelius, J. et al. (2003) J. Biol. Chem. 278:40973.
Albuquerque, R.J. et al. (2009) Nat. Med. 15:1023.
Jin, P. et al. (2008) Arthritis Res. Ther. 10:R73.
Shibuya, M. (2015) Endocr Metab Immune Disord Drug Targets. 15:135.
Farzaneh Behelgardi, M. et al. (2020), Mol Biol Rep. 47:2061.
Lian, L. et al. (2019) BMC Cancer. 19:183.
Hu, C. et al. (2019) Onco. Targets Ther. 12:933.
Gao, F. et al. (2020) Curr. Cancer Drug Targets. 20:3.

Long Name

Vascular Endothelial Growth Factor Receptor 2

Entrez Gene IDs

3791 (Human); 16542 (Mouse)

Alternate Names

CD309 antigen; CD309; EC 2.7.10; EC 2.7.10.1; Fetal liver kinase 1; fetal liver kinase-1; Flk1; Flk-1; FLK1tyrosine kinase growth factor receptor; KDR; kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein-tyrosine kinase receptor flk-1; soluble VEGFR2; vascular endothelial growth factor receptor 2; VEGF R2; VEGFR; VEGFR2; VEGFR-2